Pure Global
NCT06107595

Conditioned Open Label Placebo for Postoperative Pain Management

A Randomized Controlled Trial Evaluating the Efficacy of Conditioned Open Label Placebo (COLP) to Limit Opioid Reliance for Postoperative Pain Management
Centre de Médecine Intégrative et Complémentaire (CEMIC)·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pain, Postoperative
Drug/Device/Intervention
Placebo
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Centre de Médecine Intégrative et Complémentaire (CEMIC)
Location
Lausanne, Switzerland
Timeline & enrollment
Phase
N/A
Start date
Nov 06, 2023
End date
Dec 01, 2025
Enrollment
222 participants
Primary outcome

Opioids consumption

Summary

The primary objective is to evaluate the efficacy of two Conditioned Open Label Placebos
 (COLP): COLP pill and COLP odor to reduce opioid intake for postoperative (thoracic and
 spinal surgery) pain management compared to the opioid only usual treatment (TAU).

ICD-10 classifications
During surgical operationDuring surgical operationDuring surgical operationPain, unspecifiedPostoperative intestinal obstruction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06107595
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06107595 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre de Médecine Intégrative et Complémentaire (CEMIC) and is currently Not yet recruiting. The study focuses on Pain, Postoperative. Target enrollment is 222 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.